DelveInsight's analysts estimate that the inherited
retinal diseases market is poised to show significant growth,
mainly attributed to increasing prevalence, drug approvals, and
anticipated launch of novel therapies during the forecast period
(2023–2034).
LAS VEGAS, May 22, 2024 /PRNewswire/ -- DelveInsight's
Inherited Retinal Disease Market Insights report
includes a comprehensive understanding of current treatment
practices, inherited retinal disease emerging drugs, market share
of individual therapies, and current and forecasted market size
from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].
Key Takeaways from the Inherited Retinal Disease Market
Report
- According to DelveInsight's analysis, the market size for
inherited retinal disease is expected to grow significantly by
2034.
- As per DelveInsight's estimates, the prevalent population of
retinitis pigmentosa and choroideremia in the US was found to be
approximately 112K and
6.6K, respectively in 2021,
which as per DelveInsight's analysts, might increase by 2034.
- Leading inherited retinal disease companies such as
HuidaGene Therapeutics Co., Ltd., Cholgene Therapeutics, Inc.,
Endogena Therapeutics, Inc., Opus Genetics, Inc., Editas Medicine,
Inc., Spark Therapeutics, Inc., ProQR Therapeutics, Alkeus
Pharmaceuticals, Inc., Gyroscope Therapeutics Limited, Novartis
Pharmaceuticals, SparingVision, Unity Biotechnology, Inc., Beacon
Therapeutics, GenSight Biologics, Ocugen, AbbVie, Belite Bio, Inc,
IVERIC bio, Inc., ReNeuron Limited, and others are developing
novel inherited retinal disease drugs that can be available in the
inherited retinal disease market in the coming years.
- The promising inherited retinal disease therapies in the
pipeline include HG004, EA-2353, AAV8.hLCA5, EDIT-101,
AAV2-hRPE65v2,voretigene neparvovec-rzyl, QR-1123, ALK-001, GT005,
SPVN06, Aflibercept, rAAV2tYF-GRK1-hRPGRco, GS010, OCU410ST,
RST-001, Tinlarebant, Zimura, hRPC, among others.
Discover which therapies are expected to grab the major
inherited retinal disease market share @ Inherited Retinal
Disease Market Report
Inherited Retinal Disease Overview
Inherited retinal diseases (IRDs) encompass a diverse range of
disorders marked by either the degeneration or malfunction of
photoreceptors. These conditions often lead to significant vision
impairment, which may worsen gradually, manifesting from birth to
later stages of adulthood. The root cause of IRDs lies in genetic
mutations, disrupting the normal function of retinal cells and
consequently resulting in vision loss over time. Presently,
approximately 250 genes have been identified as contributors to
IRD, though many more remain undiscovered. Common symptoms include
challenges in low-light environments, diminished peripheral vision
leading to collisions, sensitivity to glare, and various other
visual difficulties.
Inherited Retinal Disease Epidemiology Segmentation
The inherited retinal disease epidemiology section provides
insights into the historical and current inherited retinal disease
patient pool and forecasted trends for the 7MM. It helps recognize
the causes of current and forecasted patient trends by exploring
numerous studies and views of key opinion leaders.
The inherited retinal disease market report proffers
epidemiological analysis for the study period 2020–2034 in the 7MM
segmented into:
- Total Prevalent Cases of Inherited Retinal Diseases
- Type-specific Prevalent Cases of Inherited Retinal
Diseases
- Diagnosed and Treatable Cases of Inherited Retinal
Diseases
Inherited Retinal Disease Treatment Market
So far, progress in developing treatments and cures to alter the
speed of disease advancement has been limited. However, there have
been some notable successes in clinical trials, particularly in the
realms of neurotrophic factor therapy and gene therapies. One
outstanding example of treatment success in inherited retinal
diseases is gene augmentation therapy. After almost twenty years of
development in both preclinical models and clinical trials, the FDA
approved the first gene-augmentation therapy for an IRD (Retinitis
Pigmentosa) in December 2017. This
treatment, named LUXTURNA, is intended for individuals
affected by retinal dystrophies caused by mutations in the RPE65
gene.
Researchers are actively engaged in the development and
evaluation of drugs to combat Choroideremia and similar retinal
conditions, aiming to impede or halt the deterioration of eyesight.
The genetic anomaly in Choroideremia leads to the gradual
dysfunction and subsequent death of specific retinal cells,
resulting in vision impairment. Investigations are underway into
various compounds that could sustain the vitality of these cells.
These treatments, known as neuroprotective agents, enhance retinal
health by prolonging the functionality and lifespan of affected
cells, thus decelerating the advancement of vision loss.
Regenerative therapy in the field of medicine shows great
potential in rejuvenating visual capabilities for individuals
affected by degenerative retinal conditions like Retinitis
Pigmentosa, Stargardt's macular dystrophy, and age-related macular
degeneration. Phase I/II trials involving stem cell treatments have
demonstrated significant success, with no observed systemic side
effects across the studies.
One field currently under investigation involves the utilization
of neuroprotective substances. These encompass a diverse array of
treatments designed to impede or halt the degenerative process by
fostering cell survival. Neuroprotective substances include
N-acetylcysteine (NAC)/N-acetylcysteine-amide (NACA),
Tauroursodeoxycholate acid (TUDCA), Idebenone (Raxone), and various
antioxidants. NAC has demonstrated notable efficacy as an
antioxidant in a mouse model of Retinitis Pigmentosa. Both oral and
topical administration of NAC are viable for extended treatment in
humans, exhibiting a favorable safety profile. Thus, there is solid
justification for exploring NAC's potential in treating Retinitis
Pigmentosa patients.
To know more about inherited retinal disease treatment
guidelines, visit @ Inherited Retinal Disease
Management
Inherited Retinal Disease Pipeline Therapies and Key
Companies
- HG004: HuidaGene Therapeutics Co., Ltd./Cholgene Therapeutics,
Inc.
- EA-2353: Endogena Therapeutics, Inc
- AAV8.hLCA5: Opus Genetics, Inc
- EDIT-101: Editas Medicine, Inc.
- AAV2-hRPE65v2,voretigene neparvovec-rzyl: Spark Therapeutics,
Inc.
- QR-1123: ProQR Therapeutics
- ALK-001: Alkeus Pharmaceuticals, Inc.
- GT005: Gyroscope Therapeutics Limited/Novartis
Pharmaceuticals
- SPVN06: SparingVision
- Aflibercept: Unity Biotechnology, Inc.
- rAAV2tYF-GRK1-hRPGRco: Beacon Therapeutics
- GS010: GenSight Biologics
- OCU410ST: Ocugen
- RST-001: AbbVie
- Tinlarebant: Belite Bio, Inc
- Zimura: IVERIC bio, Inc.
- hRPC: ReNeuron Limited
Learn more about the FDA-approved drugs for inherited retinal
disease @ Drugs for Inherited Retinal Disease
Treatment
Inherited Retinal Disease Market Dynamics
The dynamics of the inherited retinal disease market are
expected to change in the coming years. With over 250 genetic
mutations identified to date, the landscape of IRD diagnosis
and treatment is rapidly evolving. Genetic testing plays a
pivotal role in early detection and personalized treatment
strategies, allowing for targeted interventions tailored to
individual patients' genetic profiles. This has led to a shift
towards precision medicine approaches, with pharmaceutical
companies investing heavily in research and development to bring
innovative therapies to market.
Moreover, the growing interest from biotechnology and
pharmaceutical companies in the IRD market is fueling
competition and driving innovation. Gene therapies, in particular,
have emerged as a promising treatment modality for IRDs, with
several candidates in various stages of clinical development. The
potential for gene therapies to address the underlying
genetic causes of IRDs offers hope for patients with previously
untreatable conditions.
Furthermore, patient advocacy groups and collaborations
between academia, industry, and regulatory agencies are playing an
increasingly important role in shaping the IRD landscape. These
collaborations facilitate knowledge sharing, streamline clinical
trial processes, and advocate for improved access to care for
patients with IRDs. Additionally, initiatives aimed at raising
awareness about the importance of early diagnosis and treatment
are helping to reduce diagnostic delays and improve outcomes for
patients affected by these debilitating diseases. As the IRD market
continues to evolve, collaboration and innovation will be key
drivers in unlocking new treatment modalities and improving
the lives of patients worldwide.
Furthermore, many potential therapies are being investigated for
the treatment of inherited retinal disease, and it is safe to
predict that the treatment space will significantly impact the
inherited retinal disease market during the forecast period.
Moreover, the anticipated introduction of emerging therapies
with improved efficacy and a further improvement in the
diagnosis rate are expected to drive the growth of the
inherited retinal disease market in the 7MM.
However several factors may impede the growth of the inherited
retinal disease market. Scientifically, the intricate genetic
underpinnings of IRDs present challenges in developing targeted
therapies for the diverse array of conditions within this category.
The rarity and genetic heterogeneity of IRDs further
complicate clinical trial recruitment and therapeutic development.
Additionally, the high cost of research and development,
coupled with the small patient populations, renders IRD therapies
economically challenging for pharmaceutical companies. Moreover,
regulatory hurdles and the need for specialized infrastructure
for diagnosis and treatment further impede market
access. Overcoming these barriers demands collaborative efforts
among stakeholders, innovative financing models, and advancements
in genetic diagnostics and therapeutic technologies.
Inherited Retinal
Disease Market Report Metrics
|
Details
|
Study Period
|
2020–2034
|
Coverage
|
7MM [the United States,
the EU4 (Germany, France, Italy, and Spain) and the United Kingdom,
and Japan].
|
Key Inherited Retinal
Disease Companies
|
HuidaGene Therapeutics
Co., Ltd., Cholgene Therapeutics, Inc., Endogena Therapeutics, Inc,
Opus Genetics, Inc, Editas Medicine, Inc., Spark Therapeutics,
Inc., ProQR Therapeutics, Alkeus Pharmaceuticals, Inc., Gyroscope
Therapeutics Limited, Novartis Pharmaceuticals, SparingVision,
Unity Biotechnology, Inc., Beacon Therapeutics, GenSight Biologics,
Ocugen, AbbVie, Belite Bio, Inc, IVERIC bio, Inc., ReNeuron
Limited, and others
|
Key Pipeline Inherited Retinal Disease
Therapies
|
HG004, EA-2353,
AAV8.hLCA5, EDIT-101, AAV2-hRPE65v2,voretigene neparvovec-rzyl,
QR-1123, ALK-001, GT005, SPVN06, Aflibercept,
rAAV2tYF-GRK1-hRPGRco, GS010, OCU410ST, RST-001, Tinlarebant,
Zimura, hRPC, and
others
|
Scope of the Inherited Retinal Disease Market
Report
- Therapeutic Assessment: Inherited Retinal
Disease current marketed and emerging therapies
- Inherited Retinal Disease Market
Dynamics: Key Market Forecast Assumptions of Emerging
Inherited Retinal Disease Drugs and Market Outlook
- Competitive Intelligence Analysis: SWOT analysis
and Market entry strategies
- Unmet Needs, KOL's views, Analyst's views, Inherited Retinal
Disease Market Access and Reimbursement
Discover more about inherited retinal disease drugs in
development @ Inherited Retinal Disease Clinical Trials
Table of Contents
1.
|
Inherited Retinal
Disease Key Insights
|
2.
|
Inherited Retinal
Disease Report
Introduction
|
3.
|
Inherited Retinal
Disease Overview at a Glance
|
4.
|
Inherited Retinal
Disease Executive
Summary
|
5
|
Inherited Retinal
Disease Key Events
|
6
|
Epidemiology and Market
Forecast Methodology
|
6.
|
Disease Background and
Overview
|
7.
|
Inherited Retinal
Disease Treatment and
Management
|
8.
|
Inherited Retinal
Disease Guidelines
|
9.
|
Inherited Retinal
Disease Epidemiology and Patient
Population
|
10.
|
Patient
Journey
|
11.
|
Key Endpoints in
Inherited Retinal Disease
|
12.
|
Inherited Retinal
Disease Marketed Drugs
|
13.
|
Inherited Retinal
Disease Emerging Drugs
|
14.
|
7MM Inherited Retinal Disease Market Analysis
|
15.
|
Market Access and
Reimbursement
|
16.
|
KOL Views
|
17.
|
Unmet Needs
|
18.
|
SWOT
Analysis
|
19.
|
Appendix
|
20.
|
DelveInsight
Capabilities
|
21.
|
Disclaimer
|
22.
|
About
DelveInsight
|
Related Reports
Inherited Retinal Disease Pipeline
Inherited Retinal Disease Pipeline Insight –
2024 report provides comprehensive insights about the
pipeline landscape, pipeline drug profiles, including clinical and
non-clinical stage products, and the key IRD companies,
including Novartis Pharmaceuticals, SparingVision, Unity
Biotechnology, Inc., Beacon Therapeutics, GenSight Biologics,
Ocugen, AbbVie, Belite Bio, Inc, IVERIC bio, Inc., among
others.
Inherited Retinal Disease Epidemiology Forecast
Inherited Retinal Disease Epidemiology Forecast –
2032 report delivers an in-depth understanding of the
disease, historical and forecasted IRD epidemiology in the
7MM, i.e., the United States, EU5
(Germany, Spain, Italy,
France, and the United Kingdom), and Japan.
Retinitis Pigmentosa Market
Retinitis Pigmentosa Market Insights, Epidemiology, and
Market Forecast – 2032 report delivers an in-depth
understanding of the disease, historical and forecasted
epidemiology, as well as the market trends, market drivers, market
barriers, and key retinitis pigmentosa companies, including
Johnson & Johnson Innovative Medicine, MeiraGTx, Beacon
Therapeutics, Nanoscope Therapeutics, Gensight Biologics, 4D
Molecular Therapeutics, Coave Therapeutics, Ocugen, Bionic Sight,
jCyte, Endogena Therapeutics, ProQR Therapeutics, Aldeyra
Therapeutics, among others.
Stargardt Disease Market
Stargardt Disease Market Insights, Epidemiology, and Market
Forecast – 2032 report delivers an in-depth understanding of
the disease, historical and forecasted epidemiology, as well as the
market trends, market drivers, market barriers, and key Stargardt
disease companies, including Kubota Pharmaceuticals,
Nanoscope Therapeutics, Alkeus Pharmaceuticals, Belite Bio,
Astellas Pharma, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market
Research firm focused exclusively on life sciences. It supports
pharma companies by providing comprehensive end-to-end solutions to
improve their performance. Get hassle-free access to all the
healthcare and pharma market research reports through our
subscription-based platform PharmDelve.
Contact Us
Shruti
Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com
Logo:
https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/inherited-retinal-disease-market-size-and-share-to-grow-by-2034-assesses-delveinsight--key-companies----spark-therapeutics-alkeus-pharmaceuticals-novartis-pharmaceuticals-beacon-therapeutics-gensight-biologics-ocugen-abbvi-302152601.html